HomeMarket NewsSmall CapsAstraZeneca's Tagrisso-Chemo Combo Data In Lung Cancer Sets High Bar For Johnson...

AstraZeneca's Tagrisso-Chemo Combo Data In Lung Cancer Sets High Bar For Johnson & Johnson's Cancer Drug: Analyst

Actionable Trade Ideas

always free

azn 1

On Sunday night time,Β AstraZeneca PlcΒ AZN introduced the Part 3 FLAURA2 outcomes evaluating Tagrisso plus chemotherapy versus Tagrisso monotherapy as first-line therapy for sufferersΒ with EGFR mutant lung most cancers.Β 

The mixture resulted in a major profit in progression-free survival (PFS), with roughly a 9-month absolute enchancment in median PFS and a hazard ratio of 0.62.

William BlairΒ writes that the outcomes elevate the efficacy bar forΒ Johnson & Johnson’sΒ JNJ MARIPOSA Part 3 trial evaluating Rybrevant plus lazertinib, anticipated later this 12 months.

The analyst, Matt Phipps, additional highlights that the absence of clear traits in general survival and elevated chemotherapy-related toxicity doesn’t indicate that the FLAURA2 routine will promptly set up itself as the usual of care, a viewpoint additionally shared by AstraZeneca.Β 

Genmab A/SΒ GMAB (Market Carry out ranking) receives royalties on Rybrevant gross sales (at a fee of 8% to 10%), and any scientific developments with Rybrevant can present insights into the potential improvement trajectory and market prospects forΒ Merus N.V.’sΒ MRUS (Outperform ranking) MCLA-129.

For Genmab, the analyst anticipates peak Rybrevant gross sales approaching $1 billion by 2027, with Genmab receiving royalties of DKK 600K. The projection encompasses the anticipated development within the Exon20 mutation affected person inhabitants.Β 

Moreover, the potential enlargement of Rybrevant’s market to embody frontline EGFR mutant lung most cancers sufferers may considerably surpass our present peak gross sales estimate by a considerable margin.

As for Merus, William Blair believes the corporate stands to learn considerably from the profitable improvement of petosemtamab alone and awaits updates from the enlargement cohorts of the scientific trial later this 12 months.Β 

Worth Motion:Β AZN shares are down 2.54% at $66.49 on the final test Monday.

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.